University of Oxford - Nuffield Department of Medicine, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, University of Cambridge - Department of Genetics, University of Oxford, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford - Nuffield Department of Medicine, European Bioinformatics Institute (EMBL-EBI), University of Oxford - Nuffield Department of Medicine, Imperial College London, Harvard University - Harvard Medical School, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, University of Oxford, Nuffield Department of Medicine, John Radcliffe Hospital, Foundation for Innovative New Diagnostics (FIND), Foundation for Innovative New Diagnostics (FIND), Foundation for Innovative New Diagnostics (FIND), Foundation for Innovative New Diagnostics (FIND), World Health Organization (WHO) - Global Tuberculosis Programme, World Health Organization (WHO) - Global Tuberculosis Programme, University of Oxford - Nuffield Department of Medicine, Independent, Independent, University of Oxford - Nuffield Department of Medicine, World Health Organization (WHO) - Global Tuberculosis Programme and University of California, San Diego (UCSD)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, FISABIO-Public Health, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Baylor University, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), University of Bordeaux, Baylor University, Baylor University, University of Bordeaux, University of Bordeaux, University of Bordeaux, Government of the United States of America - National Cancer Institute, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, University of Bordeaux and Government of the United States of America - Division of Cancer Epidemiology and Genetics

University of Valencia, affiliation not provided to SSRN, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Doctor Peset University Hospital, affiliation not provided to SSRN, Hospital Clínico Universitario, Instituto de Investigación INCLIVA, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Valencia, affiliation not provided to SSRN, Castellon University - Castellon University General Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Universitari i Politècnic La Fe, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Clínico Universitario, Instituto de Investigación INCLIVA, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital General Universitario de Alicante, affiliation not provided to SSRN, affiliation not provided to SSRN, Independent, Universitat de València, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Centro de Investigação em Saúde da Manhiça (CISM), Centro de Investigação em Saúde da Manhiça (CISM), Centro de Investigação em Saúde da Manhiça (CISM), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Universitat de Barcelona, Centro de Investigação em Saúde da Manhiça (CISM), Centro de Investigação em Saúde da Manhiça (CISM), Hospital Distrital da Manhiça, University of North Carolina (UNC) at Chapel Hill - National Institute of Health, University of North Carolina (UNC) at Chapel Hill - National Institute of Health, University of North Carolina (UNC) at Chapel Hill - National Institute of Health, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, University of North Carolina (UNC) at Chapel Hill - National Institute of Health, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit, Centro de Investigação em Saúde da Manhiça (CISM), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Tuberculosis Genomics Unit and Centro de Investigação em Saúde da Manhiça (CISM)